Navigation Links
Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C
Date:1/12/2009

- Trial conducted by Novartis to evaluate safety and efficacy of Albuferon administered every four weeks in combination with ribavirin in patients with genotypes 2 and 3 hepatitis C -

ROCKVILLE, Md., Jan. 12 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that Novartis has initiated dosing in a Phase 2b trial that will evaluate the safety and efficacy of Albuferon(R) (albinterferon alfa-2b) administered monthly in combination with ribavirin in treatment-naive patients with genotypes 2 and 3 chronic hepatitis C. Albuferon is being developed by HGS and Novartis under an exclusive worldwide co-development and commercialization agreement entered into in June 2006.

(LOGO: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )

"Patients undergoing treatment for chronic hepatitis C often find it challenging to participate in normal daily activities, especially in the days following dose administration," said Stephen Pianko, M.D., F.R.A.C.P., Ph.D., Monash University, Melbourne, Australia. "Pegylated interferons, the current standard of care, require administration once every week. Albinterferon alfa-2b dosed every four weeks with a total of six injections could offer an important treatment option, if it demonstrates comparable safety and efficacy vs. peginterferon alfa-2a dosed weekly with a total of 24 injections."

In December 2008, HGS announced that Albuferon met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys) in ACHIEVE 2/3, a Phase 3 clinical trial of Albuferon in combination with ribavirin in treatment-naive patients with genotypes 2 and 3 chronic hepatitis C. In these patients, the Phase 3 study showed that 900-mcg Albuferon administered every two wee
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Denville, NJ (PRWEB) January 22, 2015 ... shearing technologies such as the Bioruptor® and complete ... semi-automation system for chromatin immunoprecipitation, alleviating the need ... reagents and controls needed for ChIP of histones ...
(Date:1/22/2015)... Jan. 22. 2015  Varian Medical Systems (NYSE: VAR ... honored for its commitment to sustainability with inclusion on a ... the highest ranked healthcare equipment company among the Corporate Knights ... World Economic Forum at Davos, Switzerland . ...
(Date:12/25/2014)... 2014 The report “Service Quality Management ... & Provider Type - Global Advancements, Worldwide Forecasts & ... in-depth analysis and forecasting of revenues. , Browse ... pages and in-depth TOC on “Service Quality Management (SQM) ...
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   ... disease, announced today that the Company closed its ... Investment Management, Jack W. Schuler , Birchview ... were $10.5 million, before offering expenses.  The proceeds ...
Breaking Biology Technology:Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Varian Honored Among World's 100 Most Sustainable Corporations 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... SAN DIEGO, July 23 Anadys Pharmaceuticals, Inc. (Nasdaq: ... financial results on Thursday, July 30, 2009, after the U.S. financial markets ... conference call and webcast on Thursday, July 30, 2009 at 5:00 p.m. ... highlights and to provide an update on its development programs. A ...
... , , , , DALLAS, ... E S S PHARMACEUTICALS, INC. ... European partner, SpePharm , is collecting data from a post approval ... UK showing prevention of oral mucositis. In a multi-center study expected to enroll ...
... Calif., July 23 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) ... 2009 Growth Stock & National Sales Conference on Thursday, July 30, 2009 ... Florida. , , More information about the ... , About Peregrine Pharmaceuticals , ...
Cached Biology Technology:Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results 2MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients 2MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients 3
(Date:1/22/2015)... POINT ROBERTS, Washington , January 20, 2015 ... including technology and tech stocks, releases video from the CES ... and security consultant Apollo Robbins . Apollo ... the Wocket™ biometric smart wallet, a product of NXT-ID, Inc. ...
(Date:1/22/2015)... Jan. 22, 2015 Infinisource has launched its new NXG ... model. The G2 sets a higher standard for collecting attendance ... management solution. With plug-and-play installation, touch screen interface and seamless ... a robust time collection solution for the small to mid-size ...
(Date:12/19/2014)... Dec. 18, 2014 Research and Markets ( ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire ... http://photos.prnewswire.com/prnh/20130307/600769 Following ... the fingerprint reading feature with the iPhone 5S. It ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Infinisource's NXG series sets new time clock standard 2iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2
... with Primary Angle Closure Glaucoma (PACG), a leading cause ... people worldwide, 80% of whom live in Asia. ... Nature Genetics , on 26 August 2012, was ... Institute (SERI)/Singapore National Eye Centre (SNEC), Genome Institute of ...
... 2012 Researchers at the Hebrew University of Jerusalem ... the autonomic nervous system -- reaches the bones and ... The newly discovered pathway has a key role in ... the skeletal resistance to fracture throughout one,s entire life, ...
... Operon, one of the pioneers and key providers of ... 2500 and an Illumina MiSeq sequencer to its fleet ... will be able to provide customers with NGS services ... Whilst technological innovation has improved the general performance of ...
Cached Biology News:Singapore scientists find genes associated with glaucoma, a major cause of eye blindness 2Singapore scientists find genes associated with glaucoma, a major cause of eye blindness 3New neural pathway controlling skeletal development discovered 2New neural pathway controlling skeletal development discovered 3
Anti-Goat HRP-DAB Cell & Tissue Staining Kit...
... Chemicon's 3243 provides all the materials necessary for ... in CMV antigen studies analysis. Kit Components: ... (Catalog No. 5122) One bottle containing 220 mL ... Fixation Solution (5X) - (Catalog No. 5113) One ...
ANTI NO-TRYPTOPHAN CONJUGATE...
GOAT ANTI SLI...
Biology Products: